Turning Point Therapeutics Stock Price, News & Analysis (NASDAQ:TPTX)

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Turning Point Therapeutics (NASDAQ:TPTX) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.05. View Turning Point Therapeutics' Earnings History.

Turning Point Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Turning Point Therapeutics.

9 brokerages have issued 1-year price objectives for Turning Point Therapeutics' shares. Their predictions range from $42.00 to $70.00. On average, they expect Turning Point Therapeutics' share price to reach $54.56 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price. View Analyst Price Targets for Turning Point Therapeutics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Turning Point Therapeutics.

Headlines about TPTX stock have been trending very positive recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Turning Point Therapeutics earned a news impact score of 3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Turning Point Therapeutics.

Turning Point Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 2,280,000 shares, an increase of 17.5% from the August 30th total of 1,940,000 shares. Based on an average daily trading volume, of 224,000 shares, the days-to-cover ratio is presently 10.2 days. Currently, 10.6% of the shares of the company are short sold. View Turning Point Therapeutics' Current Options Chain.

Some companies that are related to Turning Point Therapeutics include The Medicines (MDCO), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), United Therapeutics (UTHR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Allakos (ALLK), Reata Pharmaceuticals (RETA), Alkermes (ALKS) and Global Blood Therapeutics (GBT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include H&E Equipment Services (HEES), Immunomedics (IMMU), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Applied Genetic Technologies (AGTC), Aimmune Therapeutics (AIMT), Alkermes (ALKS), Allena Pharmaceuticals (ALNA), Alnylam Pharmaceuticals (ALNY) and Amyris (AMRS).

(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics' lock-up period expired on Monday, October 14th. Turning Point Therapeutics had issued 9,250,000 shares in its public offering on April 17th. The total size of the offering was $166,500,000 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TPTX stock can currently be purchased for approximately $36.99.

Turning Point Therapeutics has a market capitalization of $1.16 billion. Turning Point Therapeutics employs 50 workers across the globe.View Additional Information About Turning Point Therapeutics.

The official website for Turning Point Therapeutics is http://www.tptherapeutics.com/.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]